Association of a CYP4A11 variant and blood pressure in black men.

CYP4A11 arachidonic acid monooxygenase oxidizes endogenous arachidonic acid to 20-hydroxyeicosatetraenoic acid, a renal vasoconstrictor and natriuretic. Cyp4a deficiency causes hypertension in male mice, and a loss-of-function variant (T8590C) of CYP4A11 is associated with hypertension in white individuals. Hypertension and hypertensive renal disease are more common among black than white individuals, but the relationship between genetic variation at CYP4A11 and hypertension in black individuals is not known. This study tested the hypothesis that the CYP4A11 T8590C polymorphism is associated with higher BP or clinical outcomes in 732 black Americans with hypertensive renal disease participating in the African American Study of Kidney Disease (AASK). Men with the 8590CC genotype had significantly higher systolic BP (CC 156.5 +/- 22.6 versus 148.4 +/- 24.3 mmHg in CT and TT combined; P = 0.04) and pulse pressure (P = 0.04) at baseline; this association was not observed among women. In addition, this genotype was associated with higher systolic and diastolic BP at 36-mo follow-up among those randomly assigned to the lower BP arm of the AASK. Among all participants (or men but not women) with proteinuria, the 8590CC genotype was associated with an increased cumulative incidence of ESRD or death, controlling for randomization and clinical characteristics. In summary, the CYP4A11 8590CC genotype is associated with increased BP in black men with hypertensive nephrosclerosis and is associated with adverse clinical outcomes in those with baseline proteinuria. These data support a role for renal monooxygenases and 20-hydroxyeicosatetraenoic acid in the regulation of BP and renal function in men.

[1]  T. Nakayama,et al.  A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men , 2008, Journal of hypertension.

[2]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[3]  H. Baelde,et al.  Genetic factors in progressive renal disease: the good ones, the bad ones and the ugly ducklings. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  I. König,et al.  Association of the T8590C Polymorphism of CYP4A11 With Hypertension in the MONICA Augsburg Echocardiographic Substudy , 2005, Hypertension.

[5]  Keith C. Norris,et al.  Unraveling the racial disparities associated with kidney disease. , 2005, Kidney international.

[6]  B. Freedman,et al.  Genetic factors in end-stage renal disease. , 2005, Kidney international. Supplement.

[7]  M. Waterman,et al.  Functional Variant of CYP4A11 20-Hydroxyeicosatetraenoic Acid Synthase Is Associated With Essential Hypertension , 2005, Circulation.

[8]  L. Appel,et al.  A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. , 2004, Journal of the American Society of Nephrology : JASN.

[9]  M. Wellner,et al.  A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. , 2004, The American journal of pathology.

[10]  Josef Coresh,et al.  Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. , 2003, Journal of the American Society of Nephrology : JASN.

[11]  M. Kutner,et al.  Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). , 2003, Journal of the American Society of Nephrology : JASN.

[12]  Keith C. Norris,et al.  The rationale and design of the AASK cohort study. , 2003, Journal of the American Society of Nephrology : JASN.

[13]  A. Nasjletti,et al.  Differential Regulation of Natriuresis by 20-Hydroxyeicosatetraenoic Acid in Human Salt-Sensitive Versus Salt-Resistant Hypertension , 2003, Circulation.

[14]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[15]  N. Kaplan,et al.  On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles , 2002, Genetic epidemiology.

[16]  J. Lewis,et al.  Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[18]  J. Falck,et al.  The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. , 2001, Biochemical and biophysical research communications.

[19]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[20]  R. Roman,et al.  Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. , 2001, American journal of hypertension.

[21]  M. Waterman,et al.  Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Mcgiff,et al.  20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure , 2001, Current opinion in nephrology and hypertension.

[23]  H. Jacob,et al.  Evidence of gene-gene interactions in the genetic susceptibility to renal impairment after unilateral nephrectomy. , 2000, Journal of the American Society of Nephrology : JASN.

[24]  M. Carroll,et al.  A new class of lipid mediators: cytochrome P450 arachidonate metabolites , 2000, Thorax.

[25]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  J. Falck,et al.  Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. , 2000, American journal of physiology. Heart and circulatory physiology.

[27]  J. Mcgiff,et al.  20-HETE and the kidney: resolution of old problems and new beginnings. , 1999, The American journal of physiology.

[28]  J. Coresh,et al.  Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  R. Roman,et al.  Increased excretion of urinary 20-HETE in rats with cyclosporine-induced nephrotoxicity. , 2005, Journal of pharmacological sciences.

[30]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  R. Roman,et al.  P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.

[32]  C. Lewis,et al.  A genome scan for renal function among hypertensives: the HyperGEN study. , 2001, American journal of human genetics.

[33]  M. Daly,et al.  Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat , 1996, Nature Genetics.